Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users

Journal of Opioid Management

Volumn 7, Issue 3, 2011, Pages 179-192

  Schoedel, Kerri A ^a   McMorn, Stephen ^b   Chakraborty, Bijan ^a   Potts, Susan L ^b   Zerbe, Kathleen ^b   Sellers, Edward M ^a,c,d  

^a Kendle Early Stage   (Canada)

^b ENDO PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adverse effects; Drug users; Euphoria; Opioid; Oxycodone; Oxymorphone; Pharmacodynamics; Pharmacokinetics; Pupillary reflex; Subjective drug value

Indexed keywords

OXYCODONE; OXYMORPHONE; RECREATIONAL DRUG;

ABNORMAL DREAMING; ADDICTION RESEARCH CENTER INVENTORY; ADULT; ARTICLE; ATTENTION DISTURBANCE; BALANCE DISORDER; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; DRUG USE; EUPHORIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; MALE; MOOD DISORDER; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRURITUS; PUPILLOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUBJECTIVE DRUG VALUE; SUSTAINED RELEASE FORMULATION; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG USERS; ENDPOINT DETERMINATION; EUPHORIA; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXYCODONE; OXYMORPHONE; PUPIL; YOUNG ADULT;

EID: 79960452259     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0061     Document Type: Article

References (38)

1. Rauck R, Ma T, Kerwin R, et al.: Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. Pain Med. 2008; 9(7): 777-785.
2. Hale ME, Dvergsten C, Gimbel J: Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005; 6(1): 21-28. (Pubitemid 40051998)
3. Cowan DT, Wilson-Barnett J, Griffiths P, et al.: A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med. 2005; 6(2): 113-121. (Pubitemid 40590523)
4. Cowan DT, Wilson-Barnett J, Griffiths P, et al.: A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med. 2003; 4(4): 340-351.
5. Zacny JP: A possible link between sensation-seeking status and positive subjective effects of oxycodone in healthy volunteers. Pharmacol Biochem Behav. 2010; 95(1): 113-120.
6. Zacny JP, Gutierrez S: Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend. 2009; 101(1-2): 107-114.
7. Zacny JP, Gutierrez S: Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl). 2003; 170(3): 242-254. (Pubitemid 37491603)
8. United States Department of Health and Human Service, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Results from the 2008 National Survey on Drug Use and Health: National Findings. Available at http://www.drugabusestatistics.samhsa.gov/nsduh/2k8nsduh/2k8Results.cfm. Accessed March 5, 2010.
9. Green TC, Grimes Serrano JM, Licari A, et al.: Women who abuse prescription opioids: Findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend. 2009; 103(1-2): 65-73.
10. Sullivan MD, Edlund MJ, Fan MY, et al.: Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: The TROUP Study. Pain. 2008; 138(2): 440-449.
11. Manchikanti L, Singh A: Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008; 11(2 Suppl): S63-S88. (Pubitemid 351682079)
12. Sullivan MD, Edlund MJ, Fan MY, et al.: Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. 2010; 150(2): 332-339.
13. Strassels SA: Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009; 15(7): 556-562.
14. Fischer B, Cruz MF, Rehm J: Illicit opioid use and its key characteristics: A select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry. 2006; 51(10): 624-634.
15. Skinner ML, Haggerty KP, Fleming CB, et al.: Predicting functional resilience among young-adult children of opiate-dependent parents. J Adolesc Health. 2009; 44(3): 283-290.
16. Butler SF, Black R, Grimes Serrano JM, et al.: Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2010; 11(1): 81-91.
17. Katz NP, Adams EH, Benneyan JC, et al.: Foundations of opioid risk management. Clin J Pain. 2007; 23(2): 103-118.
18. Katz N: Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep. 2008; 10(1): 11-18.
19. Cicero TJ, Dart RC, Inciardi JA, et al.: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. 2007; 8(2): 157-170.
20. Walsh SL, Nuzzo PA, Lofwall MR, et al.: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008; 98(3): 191-202.
21. Comer SD, Ashworth JB, Sullivan MA, et al.: Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009; 5(4): 203-212.
22. Webster LR, Bath B, Medve RA: Opioid formulations in development designed to curtail abuse: Who is the target? Expert Opin Investig Drugs. 2009; 18(3): 255-263.
23. Purdue Pharma L.P.: OxyContin® (oxycodone HCl controlled-release tablets). Full prescribing information. Stamford, CT: Purdue Pharma L.P., 2005.
24. Endo Pharmaceuticals Inc.: OPANA® ER (oxymorphone hydrochloride extended-release tablets). Full prescribing information. Chadds Ford, PA: Endo Pharmaceuticals Inc., 2008.
25. Katz N, Rauck R, Ahdieh H, et al.: A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007; 23(1): 117-128. (Pubitemid 46191677)
26. Matsumoto AK, Babul N, Ahdieh H: Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005; 6(5): 357-366.
27. Rauck RL, Bookbinder SA, Bunker TR, et al.: The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag. 2006; 2(3): 155-166.
28. Shram MJ, Sathyan G, Khanna S, et al.: Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010; 30(1): 25-33.
29. Parasrampuria DA, Schoedel KA, Schuller R, et al.: Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol. 2007; 47(12): 1476-1488. (Pubitemid 350115303)
30. Schoedel KA, Sellers EM: Assessing abuse liability during drug development: Changing standards and expectations. Clin Pharmacol Ther. 2008; 83(4): 622-626. (Pubitemid 351417064)
31. Haertzen CA: Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep. 1966; 18(1): 163-194.
32. Comer SD, Ashworth JB, Foltin RW, et al.: The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend. 2008; 96(1-2): 1-15.
33. Kharasch ED, Hoffer C, Whittington D: Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology. 2004; 101(3): 738-743. (Pubitemid 39121654)
34. Gabrail NY, Dvergsten C, Ahdieh H: Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin. 2004; 20(6): 911-918. (Pubitemid 38821530)
35. Eissenberg T, Stitzer ML, Bigelow GE, et al.: Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther. 1999; 289(2): 936-945. (Pubitemid 29191252)
36. Walker DJ, Zacny JP: Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology (Berl). 1998; 140(2): 191-201. (Pubitemid 28538479)
37. Butler SF, Fernandez KC, Chang A, et al.: Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010; 11: 67-80.
38. Cicero TJ, Inciardi JA, Munoz A: Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005; 6(10): 662-672. (Pubitemid 41395058)